Oxygen-binding heme proteins incorporating...

Chemistry: molecular biology and microbiology – Micro-organism – tissue cell culture or enzyme using process... – Recombinant dna technique included in method of making a...

Reexamination Certificate

Rate now

  [ 0.00 ] – not rated yet Voters 0   Comments 0

Details

C435S252300, C435S320100, C435S325000, C536S023500, C530S385000

Reexamination Certificate

active

06235500

ABSTRACT:

BACKGROUND OF THE INVENTION
The present invention relates generally to oxygen-binding heme proteins, and in particular to such proteins incorporating one or more hemoglobin tetramers incorporating at least one functional, circularly-permuted globin.
As further background, blood transfusions allow trauma patients means to replenish blood loss, surgery patients to enter longer procedures with less risk, and rescue workers to bring a blood supply to accident victims. Although a transfusable blood supply provides many benefits, available blood is limited by human donations. In addition, the limited shelf-life of whole blood, disease transfer, and mismatched blood typing are problems yet to be fully addressed.
For example, the occurrence of an HIV-contaminated blood supply in the 1980's heightened awareness for a need to circumvent the problems associated with a donated blood supply. Even today, the United States Department of Health and Human Services has created a blood safety panel to examine many issues relative to donated blood, including HIV and hepatitis.
Transfused blood, containing plasma, white blood cells (leukocytes), platelets and red blood cells (erythrocytes), is generally used to carry oxygen from the lungs to the rest of the body's cells. A number of oxygen carrying solutions are being studied as alternatives to blood transfusions. In this regard, an effective blood substitute must satisfy three basic requirements. First, it must transport oxygen from lungs to tissues. Second, it must remain functional in vivo long enough to be effective; and third, it must not elicit harmful side effects. Blood substitutes studied to date include perfluorocarbons (Kaufman, R. J. (1991) in
Biotechnology of Blood
(J. Goldstein, e., Ed.) pp. 127-162, Butterworth-Heinemann, Boston), chemically modified hemoglobin from outdated human blood (Winslow, R. M. (1992)
Hemoglobin
-
based red cell substitutes,
Johns Hopkins University Press, Baltimore), and recombinant hemoglobins produced in microbial and mammalian hosts (Shen, T. -J., Ho, N. T., Simplaceanu, V., Zoiu, M., Green, B. N., Tam, M. F., & Ho, C. (1963),
PNAS USA
90, 8108-8112; Rao, M. J., Schneider, K., Chait, B. T., Chao, T. L., Keller, H. Anderson, S., Manjula, B. N., Kumar, R., & Acharya, A. S. (1994)
ACBSIB
22, 695-700).
On the subject of hemoglobin, each hemoglobin molecule is a tetramer of four smaller polypeptide subunits known as globins. A heme group, which is an iron-protoporphyrin complex, is associated with each polypeptide subunit, and is responsible for the reversible binding of a single molecule of oxygen. Normal adult hemoglobin is made up of two different kinds of polypeptide globins. A first globin, known as alpha globin, contains 141 amino acid residues. The second, known as beta globin, contains 146 amino acid residues. In normal adult hemoglobin, two of each kind of globin are arranged in the form of a truncated tetrahedron which has the overall shape of an ellipsoid.
The overall hemoglobin molecule is a 64,400 kDa protein. X-ray crystal structures show the size of HbAo to be about 64 Å×55 Å×50 Å (Fermi, G., Perutz, M. F., Shaanan, B. and Fourme, B. (1984)
Journal of Molecular Biology
175, 159). The heme prosthetic group of each alpha subunit is non-covalently bound to the subunits by Lys E10, His CD3, Val E11, and Phe CD1. In beta chains, His CD3 is replaced by Ser CD3 The heme contains an Fe++ bound by the proximal histidine. A distal histidine hovers over the iron but does not coordinate; however, this histidine could sterically and/or electronically hinder the binding of CO, which has a higher affinity for heme than O
2
, as well as hydrogen bond to iron in the deoxystate. The irons in the hemes can oxidize to the Fe+++ state, creating a nonfunctional hemoglobin (Bunn, H. F. a. F., B. G. (1986) in
Hemoglobin
-
Molecular, Genetic, and Clinical Aspects
(Dyson, J., Ed.) pp. 13-19, W. B. Saunders Company, Philadelphia).
Ligands that bind hemoglobin include CO, NO, CN—, and the most physiologically relevant ligand, O
2
. Oxygen binding occurs in a sygmoidal pattern, demonstrating the cooperativity of multiple ligand binding. It has been shown that hemoglobin can exist in at least two states, T and R. The T state is associated with the deoxygenated state of hemoglobin, while the R state is associated with ligand bound hemoglobin. A number of models have been offered to describe the shift from T to R when ligand is bound. Two primary models describe the change in states as either a concerted change from T to R or a sequential change of subunits from T to R as ligand is bound. The concerted model proposed by Monod, Wynman, and Changeux describes cooperativity resulting from the entire tetramer converting from T to R (Monod, J., Wyman, J., and Changeux, J. -P. (1965)
Journal of Molecular Biology
12, 88-118). The induced fit mode describes cooperativity as the result of an R state, ligand bound subunit inducing a neighboring T state subunit to alter to the R conformation (Koshland, D. E., Nemethy, G. and Filmer, D. (1966)
Biochemistry
5, 365-385). Recently, Ackers and co-workers have proposed a symmetry model for T to R transition which provides evidence for an intermediate state in T to R transition (Ackers, G. K., Doyle, M. L., Myers, D., and Daugherty, M. A. (1992) Science 255, 54-63). The eight intermediate ligation states have been studied using metal-substituted hemes that are unable to bind ligand. The evidence demonstrates the steepest free energy change occurs when a subsequent ligand binds the alternate alpha/beta dimer.
Ligand affinity is also dependent on a number of allosteric effectors. The effectors that lower oxygen affinity include protons (Bohr effect), 2,3 diphosphoglycerate, and chloride ions. The physiological relevance of the effectors is to enhance oxygen delivery to metabolically active cells that produce CO
2
.
Modification of human hemoglobin has been widely investigated as a means to provide a blood substitute and for other uses. Hemoglobin is a well-characterized protein, and can be altered to meet the basic requirements for an effective and safe blood substitute. Chemically modified, and more recently, recombinant forms of hemoglobin, are currently being tested in various stages of clinical trials.
Some problems arise from overproduction of recombinant hemoglobin in prokaryotes and eukaryotes. In humans, methionine aminopeptidase recognizes small, hydrogphobic residues as a signal to cleave (Hernan, R. A., Hui, H. L., Andracki, M. E., Noble, R. W., Sligar, S. G., Walder, J. A., & Walder, R. Y. (1992), Biochemistry 31, 8619-8628). Therefore, the first amino acid in postranslationally modified human hemoglobin is a valine. However, during the expression of human hemoglobin in
E. coli,
the initial methionine is not cleaved. Further,
E. coli
methionine peptidase recognizes small polar side chains, and expression in
E. coli
essentially adds a methionine to the primary sequence of both alpha and beta chains. This issue has been dealt with in two ways. A yeast expression system has been utilized in which the initial methionine is cleaved (Wagenbach, M., O'Roueke, K., Vitez, L., Wieczorek, A., Hoffman, S., Durfee, S., Tedesco, J., & Stetler, G. (1991)
Bio
-
Technology
9, 57-61). In prokaryotic production, the replacement of the first amino acid - valine - with a methionine was used in both alpha and beta chains (recombinant hemoglobin des-val) to produce a protein functionally similar to HbAo (Hernan, R. A., Hui, H. L., Andracki, M. E., Noble, R. W., Sligar, S. G., Walder, J. A., & Walder, R. Y. (1992),
Biochemistry
31, 8619-8628).
It has been reported that these overproduced hemoglobins are misassembled in the yeast and
E. coli
(Hernan, R. A., & Sligar, S. G. (1995)
JBC,
270, 26257-26264). The misassembled tetramer initially binds ligand similarly to wild type hemoglobin, but over time drifts to different tetramer substrates that bind ligand at different rates. The drift appears to be time and t

LandOfFree

Say what you really think

Search LandOfFree.com for the USA inventors and patents. Rate them and share your experience with other people.

Rating

Oxygen-binding heme proteins incorporating... does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Oxygen-binding heme proteins incorporating..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Oxygen-binding heme proteins incorporating... will most certainly appreciate the feedback.

Rate now

     

Profile ID: LFUS-PAI-O-2521835

  Search
All data on this website is collected from public sources. Our data reflects the most accurate information available at the time of publication.